secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001654954-23-010379
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q3 net loss narrows to $1.98M; paridiprubart study positive
-------------------------------------------------------------------------

- Net loss $1.98M ($0.10/sh) vs $5.79M ($0.37/sh) YoY; nine-month loss $6.65M ($0.34/sh) vs $14.74M ($1.04/sh).
- Operating expenses fell to $2.06M from $5.80M in Q3; R&D down $3.52M to $1.03M due to lower clinical and manufacturing costs.
- Cash $6.46M, working capital $5.39M at June 30, 2023; raised $4.63M YTD from share/warrant sales.
- Positive university study data for paridiprubart (EB05) against respiratory pathogens; Phase 3 ARDS study ongoing.
- Completed Phase 2b dermatitis study with favorable topline; planning vitiligo Phase 2 and systemic sclerosis Phase 2 studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/0001654954-23-010379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423010379/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer